A Study of GC33 (RO5137382) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
Status:
Completed
Trial end date:
2015-08-20
Target enrollment:
Participant gender:
Summary
This randomized, placebo-controlled, multicenter study will evaluate the efficacy and safety
of GC33 (RO5137382) in previously treated patients with unresectable advanced or metastatic
hepatocellular carcinoma. Participants will be stratified according to the level of GPC-3
expression in tumors and randomized to receive either GC33 (1600 mg intravenously) or placebo
on Days 1 and 8 of Cycle 1 and every 2 weeks thereafter. Anticipated time on study treatment
is until disease progression or unacceptable toxicity occurs.